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Calibrated BOLD is a promising technique that overcomes the sensitivity of conventional
fMRI to the cerebrovascular state; measuring either the basal level, or the task-induced
response of cerebral metabolic rate of oxygen consumption (CMRO2). The calibrated
BOLD method is susceptible to errors in the measurement of the calibration parameter
M, the theoretical BOLD signal change that would occur if all deoxygenated hemoglobin
were removed. The original and most popular method for measuringM uses hypercapnia
(an increase in arterial CO2), making the assumption that it does not affect CMRO2.
This assumption has since been challenged and recent studies have used a corrective
term, based on literature values of a reduction in basal CMRO2 with hypercapnia. This
is not ideal, as this value may vary across subjects and regions of the brain, and will
depend on the level of hypercapnia achieved. Here we propose a new approach, using
a graded hypercapnia design and the assumption that CMRO2 changes linearly with
hypercapnia level, such that we can measure M without assuming prior knowledge of
the scale of CMRO2 change. Through use of a graded hypercapnia gas challenge, we
are able to remove the bias caused by a reduction in basal CMRO2 during hypercapnia,
whilst simultaneously calculating the dose-wise CMRO2 change with hypercapnia.
When compared with assuming no change in CMRO2, this approach resulted in
significantly lower M-values in both visual and motor cortices, arising from significant
dose-dependent hypercapnia reductions in basal CMRO2 of 1.5 ± 0.6%/mmHg (visual)
and 1.8 ± 0.7%/mmHg (motor), where mmHg is the unit change in end-tidal CO2
level. Variability in the basal CMRO2 response to hypercapnia, due to experimental
differences and inter-subject variability, is accounted for in this approach, unlike previous
correction approaches, which use literature values. By incorporating measurement of,
and correction for, the reduction in basal CMRO2 during hypercapnia in the measurement
ofM-values, application of our approach will correct for an overestimation in both CMRO2
task-response values and absolute CMRO2.
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INTRODUCTION
Blood oxygenation level dependent (BOLD) functional MRI
(fMRI) signal contrast is widely used as a surrogate measure of
underlying neuronal activity (Kwong et al., 1992; Ogawa et al.,
1992). The BOLD signal is dependent on the concentration
of deoxygenated hemoglobin in blood, which is modulated by
changes in cerebral blood flow (CBF), cerebral blood volume
(CBV), and cerebral metabolic rate of oxygen consumption
(CMRO2). Significant inter-region and inter-subject variability
in the BOLD response arises due to vascular factors (Chiarelli
et al., 2007a; Lu et al., 2008), which could confound interpretation
of the underlying neuronal activity from BOLD results. The
technique termed calibrated BOLD was developed to address
this variability (Davis et al., 1998; Hoge et al., 1999). A
calibration parameter (M), defined as the theoretical BOLD
signal change that would occur if all deoxygenated hemoglobin
were removed, incorporates basal hemodynamic parameters,
along with parameters that are dependent on the specific
MRI acquisition scheme. This calibration parameter allows for
calculation of either absolute CMRO2 (Bulte et al., 2012; Gauthier
and Hoge, 2012; Wise et al., 2013), or the task-dependent relative
change in CMRO2 (Davis et al., 1998; Hoge et al., 1999). CMRO2
directly reflects tissue metabolism, so is widely considered a
more direct measurement of underlying neuronal activity than
the cerebrovascular CBF and CBV responses. However, this
approach is sensitive to errors in the measurement of M (Hoge
et al., 1999; Chiarelli et al., 2007b).
The original and most popular method for calculatingM uses
hypercapnia (an increase in arterial CO2). Typically, hypercapnia
is presented through inhalation of gasmixtures including CO2, or
through reductions in breathing depth and/or pace (e.g., breath
hold). The cerebral vasculature is sensitive to changes in partial
pressure of carbon dioxide dissolved in arterial blood (PaCO2),
such that hypercapnia is a potent vasodilator, causing increases
in CBF and CBV (Kety and Schmidt, 1948; Ito et al., 2003;
Noth et al., 2006; Chen and Pike, 2010b; Ho et al., 2011). For
calibrated BOLD, hypercapnia is assumed to be a purely vascular
stimulus, providing a change in CBF and CBV without a change
in CMRO2 (Davis et al., 1998). However, this iso-metabolic
assumption is the subject of controversy (Yablonskiy, 2011), with
literature indicating increases, decreases and no change in basal
CMRO2 with hypercapnia (Kety and Schmidt, 1948; Kliefoth
et al., 1979; Rhodes et al., 1981; Hoffman et al., 1982; Horvath
et al., 1994; Jones et al., 2005; Sicard and Duong, 2005; Chen
and Pike, 2010a; Jain et al., 2011; Xu et al., 2011). Recent human
MRI studies (Chen and Pike, 2010a; Jain et al., 2011; Xu et al.,
2011) have shown mixed results, calculating CMRO2 using the
Fick principle to combine CBF (phase contrast MRI) and OEF
(either T2- or susceptibility-based venous blood oxygenation
Abbreviations: ASL, arterial spin labeling; BOLD, blood oxygenation level
dependent (fMRI signal contrast); CMRO2, cerebral metabolic rate of oxygen
consumption; CBF, cerebral blood flow; CBV, cerebral blood volume; fMRI,
functional magnetic resonance imaging; PaCO2, partial pressure of carbon dioxide
dissolved in arterial blood; PETCO2, end-tidal partial pressure of carbon dioxide;
ROI, region of interest.
measurements). Xu et al. found a significant 13.4± 2.3% decrease
with a 5% CO2 hypercapnic challenge, whilst Chen and Pike
and Jain et al. found no significant change in basal CMRO2
with hypercapnia. Whilst these contrasting findings may arise
due to methodological differences, any CMRO2 change with
hypercapnia appears to be on the order of the measurement
accuracy of these methods. Despite this limited sensitivity, recent
calibrated BOLD studies have begun to correct for an assumed
reduction in basal CMRO2 with hypercapnia (Bulte et al., 2012),
based on these literature values (Xu et al., 2011). An appropriate
choice of CMRO2 response (or lack thereof) to hypercapnia is
important for calibrated BOLD experiments due to the sensitivity
of the method to propagation of errors in M through to the
endpoint CMRO2 calculation (Hoge et al., 1999; Chiarelli et al.,
2007b; Blockley et al., 2015).
With measurement sensitivity on the order of the changes
observed, current MR techniques are unsuited to fully
characterize the relationship between PaCO2 and CMRO2.
However, electrophysiological measurements appear to have
more sensitivity to investigate the dynamic range of mild
hypercapnia PaCO2 values. Studies in both non-human primates
and, more recently, in humans show reductions in spontaneous
neuronal oscillatory power with hypercapnia (Jones et al., 2005;
Zappe et al., 2008; Hall et al., 2011; Xu et al., 2011). We have
recently observed a linear relationship between PaCO2 and
spontaneous neuronal oscillatory power (Driver et al., 2016).
Whilst there is currently no direct relationship established
between CMRO2 and neuronal oscillatory power, they may
share similar underlying neurochemical mechanisms for their
responses to hypercapnia, specifically extracellular pH changes
modulating ATP channels (Dulla et al., 2005). Therefore, in the
following paragraphs, we explore the addition to the calibrated
BOLD technique of an assumption of a linear relationship
between hypercapnia level and CMRO2.
In this work, we present a new approach, relaxing the
iso-metabolic hypercapnia assumption in the calibrated BOLD
technique. By acquiring multiple levels of hypercapnia, M and
the dose-wise CMRO2 response to hypercapnia are solved for as
two unknowns in a set of simultaneous equations (one equation
for each hypercapnia level). We apply this approach to data
presented previously (Murphy et al., 2013), measuring both the
calibration parameter M and the dose-wise CMRO2 response to
a graded hypercapnia challenge.
MATERIALS AND METHODS
Theory
The calibrated BOLD equation, as proposed by Davis et al. (1998)
and elegantly restated by Hoge et al. (1999) can be used to model
the BOLD signal change during hypercapnia:
1BOLDHC
BOLD0
= M
[
1−
(
CBFHC
CBF0
)α−β
·
(
CMRO2,HC
CMRO2,0
)β]
(1)
Where M is the calibration parameter, 1 denotes the difference
between the current state and baseline state, subscripts HC and
0 denote hypercapnia and baseline (normocapnia) conditions,
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respectively. The exponent α describes an assumed coupling
relationship between CBF and CBV (Grubb et al., 1974; Chen
and Pike, 2010b), whilst β is a power-law relationship between
venous blood oxygenation and transverse relaxation rate (Ogawa
et al., 1993; Boxerman et al., 1995; Driver et al., 2010; Croal et al.,
2017). If the iso-metabolic assumption were used, the CMRO2
term would reduce to 1, with numerator and denominator being
equal. M could then be calculated from Equation (1) using
measured values for the relative changes in BOLD and CBF due
to hypercapnia.
We propose to remove the iso-metabolic assumption, such
that the CMRO2 term becomes an unknown parameter to be
solved alongside M. To do this, we measure BOLD and CBF
responses to two levels of hypercapnia, setting up two versions
of Equation (1). Since the CMRO2 term may change between
the two equations, we assume a linear relationship between
CMRO2 and hypercapnia level. A new parameter κ is defined
as the dose-wise fractional CMRO2 change to a unit (1 mmHg)
change in end-tidal partial pressure of carbon dioxide (PETCO2),
a surrogate measure for PaCO2.
CMRO2,HC
CMRO2,0
= 1+ κ ·1PETCO2 (2)
Substituting Equation 2 into Equation 1:
1BOLDHC
BOLD0
= M
[
1−
(
CBFHC
CBF0
)α−β
· (1+ κ ·1PETCO2)
β
]
(3)
Therefore, with PETCO2 measured by sampling exhaled gas, M
and κ are two unknowns, which can be solved for using two
equations, one for each hypercapnia level.
Data Acquisition
Fifteen subjects (7M/8F, age range 21–36 years) participated in 2
sessions in which scans were acquired using a 3 T whole body
MRI system (GE Excite HDx, Milwaukee, WI, USA) with an
eight-channel receive coil. The School of Psychology, Cardiff
University Ethics Committee approved this study and subjects
gave written informed consent prior to participating.
Data were acquired using a pulsed arterial spin labeling
(ASL) proximal inversion and control for off-resonance effects
(PICORE), quantitative imaging of perfusion using a single
subtraction (PICORE QUIPSS II) (Wong et al., 1998) imaging
sequence. This sequence used a dual-echo gradient echo readout
(Liu et al., 2002) and spiral-out k-space acquisition [Glover, 1999;
490 repetitions (image volumes), TE1 = 3.3 ms TE2 = 29 ms,
TR = 2,200 ms, flip angle 90◦, FOV 22 cm, matrix 64 × 64, 12
slices of 7 mm thickness with an inter-slice gap of 1 mm, TI1
= 600 ms, TI2 = 1,500 ms for the most proximal slice, 10 cm
inversion slab thickness, adiabatic hyperbolic secant inversion
pulse, 10 mm gap between labeling slab and bottom slice, 10 cm
QUIPSS II saturation band thickness]. Additionally, whole brain
T1-weighted structural scan (fast spoiled gradient recalled echo,
1 × 1 × 1 mm voxels, TI/TR/TE = 450/7.8/3 ms) was acquired
for segmentation of gray matter.
Participants were presented with hypercapnia levels of
+4 and +8 mmHg 1PETCO2 above their normal resting
level. End-tidal CO2 levels were changed at 2-min intervals
between baseline, +4 and +8 mmHg values, in a randomized
order. This provided three 2-min blocks for each condition,
across the 18 min ASL scan. Gas mixtures were delivered
to the subject through a tight-fitting face-mask (Quadralite,
Intersurgical, Wokingham, Berkshire, UK). Flow rates of two
gas mixtures, namely medical air (21% O2, 79% N2) and a
5% CO2 mixture (5% CO2, 20% O2, 75% N2), were manually
adjusted to provide an inspired gas mixture of 30 L/min. The
respiratory circuit included a reservoir on the expired limb
to permit re-breathing in the event that the instantaneous
inspiratory rate exceeded 30 L/min. Expired gas concentrations
were sampled from the face-mask and PETCO2 and PETO2
(end-tidal pO2) were measured using rapidly responding gas
analyzers (AEI Technologies, Pittsburgh, PA, USA). A manual
feedback procedure was used to reach each hypercapnia
level, whereby the respective flow rates of medical air and
the 5% CO2 mixture were adjusted to reach the PETCO2
target.
A combined visual and motor task was simultaneously
performed, consisting of blocks of 8 Hz flashing checkboard and
right-handed self-paced finger tapping with a range of block
durations between 20 and 30 s. These blocks were interspersed
with 20–30 s blocks of rest. The range in task and rest block
durations were chosen so that the visual, motor and CO2 tasks
had minimal correlation with each other. The task data was used
to define primary visual and motor cortex ROIs.
Data Analysis
CBF time series were calculated from the first echo by separating
tag and control time series, interpolating to the TR and
subtracting. A similar procedure using averaging rather than
subtraction yielded BOLD time series from the second echo. R2
∗
was also calculated by performing an exponential fit across the
two echo times, separately for tag and control time series, then
combining tag and control R2
∗ values by surround averaging.
A gray matter (GM) ROI was calculated for each subject by
segmenting their anatomical image into three tissue types (gray
matter, white matter and cerebrospinal fluid) using FSL’s fast.
The GM map was resampled to the functional data resolution.
Visual and motor ROIs were calculated by including CO2, visual
and motor timings in a voxel-wise GLM for both the BOLD
and CBF data. The results for each subject were transformed
into MNI space and a voxel-wise t-test against 0 across subject
was performed. The t-test maps were FDR thresholded at p
= 0.05. The resulting BOLD and CBF activation maps were
transformed back into individual subject space. The visual and
motor ROIs were then calculated for each subject by taking
an intersection map between the BOLD activation map, the
CBF activation map and the individual GM ROI. Therefore, a
voxel was only included in the motor ROI if it significantly
responded to the motor task in both the BOLD and CBF data and
was present in the individual’s GM mask. A similar procedure
was used for the visual ROI. Once the ROIs were defined,
the BOLD and CBF time series were averaged over the visual,
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motor, and GM ROIs, then linear detrending was performed
using baseline periods, before averaging across sessions for each
subject.
BOLD and CBF responses to each hypercapnia level
(relative to baseline) were input into +4 and +8 mmHg
versions of Equation (3), then these two equations were solved
simultaneously for M and κ , using a two-parameter non-linear
fitting routine (lsqcurvefit, Matlab, The MathWorks, Natick,
USA). Subjects that reached the boundary conditions of the
non-linear fitting routine were removed from further analysis
(boundary conditions 1<M<20%; −5< κ < +5%/mmHg). For
comparison with the iso-metabolic assumption, the same two
equations as above (+4 and +8 mmHg versions of Equation 3)
were solved simultaneously using a one-parameter fit, to calculate
M whilst fixing κ = 0.
Optimized values of α= 0.14 and β= 0.91 were used (Griffeth
and Buxton, 2011), hereafter referred to as the empirically derived
α/β pairing. To ensure that our findings were not biased by
choice of this α/β pairing, we also repeated the non-linear fitting
with the following two alternative α/β pairings that have been
used previously for calibrated BOLD experiments at 3 T. Values
of α = 0.2 and β = 1.3 have been used at 3 T (Bulte et al., 2012),
hereafter referred to as the 3 T specific α/β pairing. Finally, a
simplified model has been proposed recently, substituting α/β for
a single parameter θ = 0.06 at 3 T (Merola et al., 2016). In this
case, this simplified model is equivalent to α = 0.06 and β = 1,
hereafter referred to as the simplified model α/β pairing.
RESULTS
The two levels of hypercapnia resulted in 1PETCO2 increases of
4.8 ± 0.3 and 8.4 ± 0.4 mmHg (mean ± SEM across subjects).
BOLD and CBF responses to the two levels of hypercapnia and
the respective task (where applicable) are presented for visual,
motor cortices and the remaining GM in Table 1. To assess
BOLD sensitivity at the 29 ms TE, baseline R2
∗ is also reported
for each ROI in Table 1. Group-average maps (MNI space) of the
BOLD and CBF responses to the two levels of hypercapnia are
shown in Figure 1.
For results presented based on either the two- or one-
parameter fits, the number of subjects included after discarding
those that reached the boundary conditions are presented in
the form (N = #/15), where # corresponds to the number of
subjects included. The two-parameter fit with the empirically
derived α/β pairing (0.14/0.91) gaveM = 9.6± 1.3% (N = 14/15)
and M = 4.7 ± 0.6% (N = 13/15), in the visual and motor
cortices respectively and M = 8.6 ± 0.9% (N = 15/15) in
the remaining GM. The dose-dependent hypercapnia CMRO2
parameter κ = −1.5 ± 0.6%/mmHg, κ = −1.8 ± 0.7%/mmHg
and κ = −1.3 ± 0.4%/mmHg showed significant reductions in
CMRO2 with hypercapnia level (Wilcoxon p = 0.04, p = 0.03,
and p = 0.002). The two-parameter fit resulted in significantly
lower M-values than the one-parameter fit for subjects that did
not reach the boundary conditions for both fits [Figure 2; visual
p = 0.04, (N = 9/15); motor p = 0.008, (N = 13/15); GM
p= 0.001, (N = 14/15)].
TABLE 1 | BOLD and CBF responses (% change from baseline) for the two
hypercapnia levels and for the visual and motor tasks (mean ± SEM
across subjects).
ROI 1PETCO2(mmHg) %BOLD %CBF Baseline R2* (s
−1)
Visual 4.8 ± 0.3 0.9 ± 0.3 13 ± 3 31.3 ± 1.6
8.4 ± 0.4 1.7 ± 0.3 19 ± 4
0 (+ Task) 1.7 ± 0.1 33 ± 3
Motor 4.8 ± 0.3 0.8 ± 0.1 30 ± 15 22.3 ± 0.7
8.4 ± 0.4 1.4 ± 0.2 43 ± 16
0 (+ Task) 1.3 ± 0.1 73 ± 19
GM 4.8 ± 0.3 1.0 ± 0.1 13 ± 2 31.7 ± 0.9
8.4 ± 0.4 1.6 ± 0.1 17 ± 3
Baseline R2* values are also presented for each ROI.
The effect of changing the α/β pairing is assessed in
Figures 3, 4. Figure 3 shows a scatter plot of κ across subjects for
each α/β pairing and each region of interest, with mean ± SEM
across subjects presented above. The group-averaged κ-values
remain stable across α/β pairings, indicating a robust decrease
in CMRO2 during hypercapnia. Figure 4 presents M values
across α/β pairings. Despite the amplitude of M varying with
α/β pairing, M calculated using the two-parameter fit was
consistently lower than that calculated using the one-parameter
(iso-metabolic) fit.
DISCUSSION
Through use of a graded hypercapnia gas challenge, we are
able to remove the bias caused by a reduction in basal CMRO2
during hypercapnia, whilst simultaneously calculating the dose-
wise CMRO2 change with hypercapnia.We observed consistently
lower M-values when calculated from our new approach,
compared to those calculated using an iso-metabolic hypercapnia
assumption, evidence for a systematic overestimation of M
when using the iso-metabolic assumption. In terms of studies
calculating the relative change in CMRO2 to a task, this
overestimation in M would result in an overestimation in the
CMRO2 task response (see Equation 1, replacing hypercapnia
terms with the equivalent task response terms). In terms
of studies investigating absolute CMRO2 measurements, the
overestimation inM would lead to an overestimation of absolute
CMRO2 (Blockley et al., 2015).
In this study, we define a dose-wise CMRO2 response to
hypercapnia, κ . Our findings suggest a decrease in CMRO2 with
hypercapnia in the primary visual and motor cortices, as well
as in the remaining GM. The scale of the CMRO2 reduction is
broadly similar to that observed by Xu et al. (2011), where their
5% CO2 challenge resulted in a 13.4% decrease in global CMRO2.
Based on the reported average 1PETCO2 of 8.7 mmHg, this is
equivalent to κ = −1.5%/mmHg. This is within the range of the
GM value that we measured of κ = −1.3 ± 0.4%/mmHg. Unlike
previous work, which measured the global CMRO2 response
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FIGURE 1 | Group-average maps of BOLD and CBF responses to the +4 and +8 mmHg 1PETCO2 hypercapnia conditions. The three slices shown are at
the level of MNI coordinate Z = +12, +28, and +42 mm, respectively.
FIGURE 2 | Comparison of M (mean ± SEM) calculated using the empirically derived α/β pairing (0.14/0.91) from the two-parameter (1CMRO2 varies
linearly with 1PETCO2) and one-parameter (iso-metabolic) models for subjects that did not reach the boundary conditions for both fits (visual cortex
N = 9; motor cortex N = 13; remaining GM N = 14). *p < 0.05.
to hypercapnia, our approach can provide measurements that
are localized to specific brain regions. Our initial findings
hint at some spatial heterogeneity in the CMRO2 response to
hypercapnia, with the hypercapnia CMRO2 reduction appearing
to be greater in the motor than visual cortex. However, this
dataset does not have the sensitivity to resolve whether this is
a significant difference (see inter-subject variability in Figure 3).
Likewise, the paradigm used here is not optimized for voxelwise
mapping of M and κ , however with a suitably optimized
graded hypercapnia paradigm design that enhances voxelwise
sensitivity, this approach could be translated to mapping M and
κ , for application in mapping absolute CMRO2. The potential
spatial heterogeneity of the CMRO2 response to hypercapnia
will be investigated in future studies, incorporating a specifically
optimized hypercapnia paradigm and amore sophisticated fitting
algorithm (Germuska et al., 2016). This approach for mapping
the CMRO2 response to hypercapnia should be considered in
the context of a potential alternative, O-15 PET. There is an
extensive literature on mapping CBF and CMRO2 using O-15
PET (e.g., Mintun et al., 1984; Ter-Pogossian and Herscovitch,
1985; Kudomi et al., 2013). Whilst there are many studies to
use O-15 PET to measure the CBF response to hypercapnia
(e.g., Ito et al., 2003), the O-15 PET literature on mapping the
CMRO2 response to hypercapnia is limited, with no change in
CMRO2 measured in anesthetized dogs (Rhodes et al., 1981).
The steady-state variant of the CMRO2 measurement used in
that work may also be biased by not accounting for intravascular
15O2 (Lammertsma and Jones, 1983; Lammertsma et al., 1983;
Ter-Pogossian and Herscovitch, 1985). Whilst our method is
constrained by the accuracy of the assumptions associated with
the calibrated BOLD technique (Hoge et al., 1999; Chiarelli et al.,
2007b; Chen and Pike, 2010b; Blockley et al., 2015; Croal et al.,
2017), it is non-invasive, not requiring use of radioactive tracers.
It also has the potential for finer temporal and spatial resolution
than O-15 PET.
The approach we present here requires an assumption as to
the form of the relationship between CMRO2 and PaCO2; in this
case, the assumption is of a linear relationship. Beyond the linear
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FIGURE 3 | Plot of κ across subjects for each α/β pairing, for visual cortex, motor cortex, and the remaining GM. Diamonds show mean κ across subjects.
The values presented at the top are mean ± SEM across subjects for κ, with bold text and *indicating p(κ 6=0) < 0.05 (Wilcoxon sign rank test). The numbers of
subjects included after discarding those that reached the boundary conditions are presented in the form (N = #/15) at the bottom of each plot.
relationship, no prior assumption is made as to whether CMRO2
increases, decreases or remains constant with hypercapnia. This
linear assumption is also implicitly made as part of the iso-
metabolic assumption, or when using previous literature values
for a CMRO2 decrease. The linear relationship between CMRO2
and hypercapnia level is based on our recent observations of a
linear relationship between hypercapnia level and spontaneous
neuronal oscillatory power (Driver et al., 2016). Whilst there is
currently no direct relationship established between CMRO2 and
neuronal oscillatory power, they may share similar underlying
neurochemical mechanisms for their responses to hypercapnia,
specifically extracellular pH changes modulating ATP channels
(Dulla et al., 2005). Even if the relationship includes some non-
linearity, bias introduced by a linear correction will be smaller
than the bias from no correction.
The constrained non-linear fitting performed here to solve
for M and κ imposed boundary conditions on these parameters.
These boundary conditions 1<M<20%; −5< κ < +5%/mmHg
were chosen to be sufficiently broad to include the range of
values that would be reasonably expected when averaging across
these regions of interest, based on previous literature (Leontiev
and Buxton, 2007; Chiarelli et al., 2007a; Mark et al., 2011; Xu
et al., 2011). Therefore, where the fitting algorithms returned
values that reached these boundary conditions, this is likely to
be due to noise in the data, most likely the ASL data, rather
than being an actual physiological outlier. It is for this reason
that we chose to discard results where the boundary condition
was reached, an approach we have taken previously (Murphy
et al., 2013; Wise et al., 2013). Out of the 18 versions of
the non-linear fitting (three ROIs over three α/β pairings for
each of the two- and one-parameter fits), 14 had either one
or no subjects reaching the boundary condition. There were 3
occasions where more than two subjects reached the boundary
condition, all occurring in the visual ROI for the one-parameter
fit, 5 subjects each for the 0.14/0.91 and 0.2/1.3 α/β pairings
and 4 subjects for the 0.06/1 α/β pairing. This is consistent
with the visual ROI dataset containing more variance than the
motor and remaining GM ROIs (see errorbars in Figure 4).
Further, a BOLD-weighted second echo time of 29 ms used
here has been optimized previously for BOLD contrast, based
on GM-averaged R2
∗ (Wise et al., 2013; Germuska et al., 2016).
The 29 ms echo time is optimal for BOLD contrast for the
R2
∗ values measured here in visual and GM ROIs (Table 1),
however the smaller R2
∗ measured in the motor ROI means
that BOLD contrast in this ROI is ∼10% lower than it would
have been if a longer echo time, specifically optimized for the
motor ROI, were used. However, since the BOLD contrast is
significantly above the noise, this lower BOLD contrast in the
motor ROI will have a negligible impact on BOLD sensitivity and
will be incorporated into M, not impacting on quantification of
CMRO2.
In conclusion, we present a new approach to calibrated BOLD,
relaxing the iso-metabolic hypercapnia assumption, whilst
measuring the dose-wise change in CMRO2 due to hypercapnia.
This approach can map local CMRO2 responses to hypercapnia,
so may be suitable for measuring spatial heterogeneity in these
responses. This approach may be especially applicable in studies
including metabolic pathology, such as diabetes, dementia, and
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FIGURE 4 | Plots of M (mean ± SEM) for each α/β pairing, comparing M calculated from the two-parameter (1CMRO2 varies linearly with 1PETCO2)
and one-parameter (iso-metabolic) models for subjects that did not reach the boundary conditions for both fits. The values presented at the top of each
plot are Wilcoxon sign rank p-values, testing whether M differs between two- and one-parameter fits (*p < 0.05).
multiple sclerosis, where there may be inter- and/or intra-subject
differences in the CMRO2 response to hypercapnia. Further,
as well as the calibrated BOLD endpoints of measuring task-
dependent CMRO2, or absolute CMRO2, the measurement of
the CMRO2 response to hypercapnia could become a tool for
investigating cerebral metabolic health in its own right.
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